Cargando…
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer
BACKGROUND: Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC). PURPOSE: To investigate whether pretreatment MRI‐based radiomic signatures predict disease‐specific survival (DSS) in CC. STUDY TYPE: Retrospective. POPULATION: CC patients (n = 133) all...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652318/ https://www.ncbi.nlm.nih.gov/pubmed/37840437 http://dx.doi.org/10.1002/cam4.6526 |
_version_ | 1785136182805397504 |
---|---|
author | Wagner‐Larsen, Kari S. Hodneland, Erlend Fasmer, Kristine E. Lura, Njål Woie, Kathrine Bertelsen, Bjørn I. Salvesen, Øyvind Halle, Mari K. Smit, Noeska Krakstad, Camilla Haldorsen, Ingfrid S. |
author_facet | Wagner‐Larsen, Kari S. Hodneland, Erlend Fasmer, Kristine E. Lura, Njål Woie, Kathrine Bertelsen, Bjørn I. Salvesen, Øyvind Halle, Mari K. Smit, Noeska Krakstad, Camilla Haldorsen, Ingfrid S. |
author_sort | Wagner‐Larsen, Kari S. |
collection | PubMed |
description | BACKGROUND: Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC). PURPOSE: To investigate whether pretreatment MRI‐based radiomic signatures predict disease‐specific survival (DSS) in CC. STUDY TYPE: Retrospective. POPULATION: CC patients (n = 133) allocated into training((T)) (n (T) = 89)/validation((V)) (n (V) = 44) cohorts. FIELD STRENGTH/SEQUENCE: T2‐weighted imaging (T2WI) and diffusion‐weighted imaging (DWI) at 1.5T or 3.0T. ASSESSMENT: Radiomic features from segmented tumors were extracted from T2WI and DWI (high b‐value DWI and apparent diffusion coefficient (ADC) maps). STATISTICAL TESTS: Radiomic signatures for prediction of DSS from T2WI (T2(rad)) and T2WI with DWI (T2 + DWI(rad)) were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression. Area under time‐dependent receiver operating characteristics curves (AUC) were used to evaluate and compare the prognostic performance of the radiomic signatures, MRI‐derived maximum tumor size ≤/> 4 cm (MAX(size)), and 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–II/III–IV). Survival was analyzed using Cox model estimating hazard ratios (HR) and Kaplan–Meier method with log‐rank tests. RESULTS: The radiomic signatures T2(rad) and T2 + DWI(rad) yielded AUC(T)/AUC(V) of 0.80/0.62 and 0.81/0.75, respectively, for predicting 5‐year DSS. Both signatures yielded better or equal prognostic performance to that of MAX(size) (AUC(T)/AUC(V): 0.69/0.65) and FIGO (AUC(T)/AUC(V): 0.77/0.64) and were significant predictors of DSS after adjusting for FIGO (HR(T)/HR(V) for T2(rad): 4.0/2.5 and T2 + DWI(rad): 4.8/2.1). Adding T2(rad) and T2 + DWI(rad) to FIGO significantly improved DSS prediction compared to FIGO alone in cohort((T)) (AUC(T) 0.86 and 0.88 vs. 0.77), and FIGO with T2 + DWI(rad) tended to the same in cohort((V)) (AUC(V) 0.75 vs. 0.64, p = 0.07). High radiomic score for T2 + DWI(rad) was significantly associated with reduced DSS in both cohorts. DATA CONCLUSION: Radiomic signatures from T2WI and T2WI with DWI may provide added value for pretreatment risk assessment and for guiding tailored treatment strategies in CC. |
format | Online Article Text |
id | pubmed-10652318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106523182023-10-16 MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer Wagner‐Larsen, Kari S. Hodneland, Erlend Fasmer, Kristine E. Lura, Njål Woie, Kathrine Bertelsen, Bjørn I. Salvesen, Øyvind Halle, Mari K. Smit, Noeska Krakstad, Camilla Haldorsen, Ingfrid S. Cancer Med RESEARCH ARTICLES BACKGROUND: Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC). PURPOSE: To investigate whether pretreatment MRI‐based radiomic signatures predict disease‐specific survival (DSS) in CC. STUDY TYPE: Retrospective. POPULATION: CC patients (n = 133) allocated into training((T)) (n (T) = 89)/validation((V)) (n (V) = 44) cohorts. FIELD STRENGTH/SEQUENCE: T2‐weighted imaging (T2WI) and diffusion‐weighted imaging (DWI) at 1.5T or 3.0T. ASSESSMENT: Radiomic features from segmented tumors were extracted from T2WI and DWI (high b‐value DWI and apparent diffusion coefficient (ADC) maps). STATISTICAL TESTS: Radiomic signatures for prediction of DSS from T2WI (T2(rad)) and T2WI with DWI (T2 + DWI(rad)) were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression. Area under time‐dependent receiver operating characteristics curves (AUC) were used to evaluate and compare the prognostic performance of the radiomic signatures, MRI‐derived maximum tumor size ≤/> 4 cm (MAX(size)), and 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–II/III–IV). Survival was analyzed using Cox model estimating hazard ratios (HR) and Kaplan–Meier method with log‐rank tests. RESULTS: The radiomic signatures T2(rad) and T2 + DWI(rad) yielded AUC(T)/AUC(V) of 0.80/0.62 and 0.81/0.75, respectively, for predicting 5‐year DSS. Both signatures yielded better or equal prognostic performance to that of MAX(size) (AUC(T)/AUC(V): 0.69/0.65) and FIGO (AUC(T)/AUC(V): 0.77/0.64) and were significant predictors of DSS after adjusting for FIGO (HR(T)/HR(V) for T2(rad): 4.0/2.5 and T2 + DWI(rad): 4.8/2.1). Adding T2(rad) and T2 + DWI(rad) to FIGO significantly improved DSS prediction compared to FIGO alone in cohort((T)) (AUC(T) 0.86 and 0.88 vs. 0.77), and FIGO with T2 + DWI(rad) tended to the same in cohort((V)) (AUC(V) 0.75 vs. 0.64, p = 0.07). High radiomic score for T2 + DWI(rad) was significantly associated with reduced DSS in both cohorts. DATA CONCLUSION: Radiomic signatures from T2WI and T2WI with DWI may provide added value for pretreatment risk assessment and for guiding tailored treatment strategies in CC. John Wiley and Sons Inc. 2023-10-16 /pmc/articles/PMC10652318/ /pubmed/37840437 http://dx.doi.org/10.1002/cam4.6526 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Wagner‐Larsen, Kari S. Hodneland, Erlend Fasmer, Kristine E. Lura, Njål Woie, Kathrine Bertelsen, Bjørn I. Salvesen, Øyvind Halle, Mari K. Smit, Noeska Krakstad, Camilla Haldorsen, Ingfrid S. MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title |
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title_full |
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title_fullStr |
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title_full_unstemmed |
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title_short |
MRI‐based radiomic signatures for pretreatment prognostication in cervical cancer |
title_sort | mri‐based radiomic signatures for pretreatment prognostication in cervical cancer |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652318/ https://www.ncbi.nlm.nih.gov/pubmed/37840437 http://dx.doi.org/10.1002/cam4.6526 |
work_keys_str_mv | AT wagnerlarsenkaris mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT hodnelanderlend mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT fasmerkristinee mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT luranjal mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT woiekathrine mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT bertelsenbjørni mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT salvesenøyvind mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT hallemarik mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT smitnoeska mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT krakstadcamilla mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer AT haldorseningfrids mribasedradiomicsignaturesforpretreatmentprognosticationincervicalcancer |